Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis
Syndax offers a de-risked dual-product biotech growth inflection, with asymmetric upside tied to Revuforj frontline expansion and Niktimvo’s potential IPF breakthrough.
Overview
Syndax is now a commercial-stage biopharma company with two FDA-approved assets: Revuforj for genetically defined relapsed/refractory leukemias and Niktimvo for chronic graft-versus-host disease. Revenue is concentrated in the U.S., where Syndax books all Revuforj sales and shares Niktimvo profits with Incyte. Both products address high-unmet-need specialist markets with limited targeted alternatives. The thesis rests on commercial ramp-up, label expansion, longer treatment duration, and pipeline optionality, particularly Niktimvo in IPF.